开放与分期开窗/分支腔内修复胸腹主动脉瘤的院内成本效果分析
单中心回顾性观察研究(PRO-ENDO TAAA,NCT05266781)纳入2013至2021年择期治疗的胸腹主动脉瘤,倾向匹配102对。开放修复组围术期死亡率和主要不良事件更高,但腔内修复组器械费用更高使总费用增加80%。腔内修复组每避免一例主要不良事件增量成本效果比为48,409欧元。
要点
- 开放修复组死亡率13% vs 腔内修复组5%(P = .048),主要不良事件60% vs 17%(P < .001)。
- 腔内修复组进入并发症率6% vs 开放修复组27%(P < .001),但总费用因器械费用增加80%。
- 腔内修复组每避免一例主要不良事件的增量成本效果比为48,409欧元。
核心结论
- 择期胸腹主动脉瘤腔内修复较开放修复降低围术期死亡率和并发症,中期再干预率和生存率无差异。
- 尽管腔内移植物费用较高,腔内修复在预防主要不良事件方面更具成本效果。
研究设计与样本
- 单中心回顾性观察研究(PRO-ENDO TAAA Study,NCT05266781),为大型卫生技术评估分析的一部分。
- 分析2013年至2021年所有择期治疗的胸腹主动脉瘤,并进行倾向匹配,匹配出102对患者(共789例胸腹主动脉瘤)。
- 终点为临床成功、主要不良事件、住院直接费用、全因死亡率和动脉瘤相关死亡率及再干预豁免率。
主要发现
- 开放修复组死亡率13% vs 腔内修复组5%(P = .048)。
- 开放修复组主要不良事件60% vs 腔内修复组17%(P < .001)。
- 开放修复组永久性脊髓缺血10% vs 腔内修复组3%(P = .045),呼吸并发症91% vs 18%(P < .001),心脏并发症16% vs 6%(P = .024),肾损伤27% vs 6%(P < .001)。
- 腔内修复组进入并发症率6% vs 开放修复组27%(P < .001)。
- 开放修复组重症监护室住院时间更长(P < .001),腔内修复组出院回家比例3% vs 94%(P < .001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare costs and effectiveness of elective open (OR) vs fenestrated/branched endovascular (ER) repair of thoracoabdominal aneurysms (TAAAs) in a high-volume center. METHODS: This single-center retrospective observational study (PRO-ENDO TAAA Study, NCT05266781) was designed as part of a larger health technology assessment analysis. All electively treated TAAAs between 2013 and 2021 were analyzed and propensity-matched. End points were clinical success, major adverse events (MAEs), hospital direct costs, and freedom from all causes and aneurysm-related mortality and reinterventions. Risk factors and outcomes were homogeneously classified according to the Society of Vascular Surgery reporting standards. Cost-effectiveness value and incremental cost-effectiveness ratio were calculated, considering the absence of MAEs as a measure of effectiveness. RESULTS: Propensity matching identified 102 pairs of patients out of 789 TAAAs. Mortality, MAE, permanent spinal cord ischemia rates, respiratory complications, cardiac complications, and renal injury were higher for OR (13% vs 5%, P = .048; 60% vs 17%, P < .001; 10% vs 3%, P = .045; 91% vs 18%, P < .001; 16% vs 6%, P = .024; 27% vs 6%, P < .001, respectively). Access complication rate (6% vs 27%; P < .001) was higher in the ER group. Intensive care unit stay was longer (P < .001) for OR, and ER patients were discharged home more frequently (3% vs 94%; P < .001). No differences in midterm end points were observed at 2 years. Despite ER reducing all the hospital cost items (-42% to -88%, P < .001), the higher expenses (P < .001) of the endovascular devices increased the overall cost of ER by 80%. Cost-effectiveness value for ER was favorable to OR (56,365 vs 64,903 €/patient) with an incremental cost-effectiveness ratio of 48,409 € per MAE saved. CONCLUSIONS: ER of TAAA reduces perioperative mortality and morbidity compared with OR, with no differences in reinterventions and survival rates at midterm follow-up. Despite the expenses for endovascular grafts, ER was found to be more cost-effective in preventing MAEs.
引用
- Bertoglio L, Melloni A, Bugna C, et al. In-hospital cost-effectiveness analysis of open versus staged fenestrated/branched endovascular elective repair of thoracoabdominal aneurysms. J Vasc Surg. 2023. PMID: 37076108. doi:10.1016/j.jvs.2023.03.503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。